Patient Access to Medicines for Rare Diseases in European Countries

Value in Health

Volumn 21, Issue 5, 2018, Pages 553-560

  Detiček, Andreja ^a   Locatelli, Igor ^a   Kos, Mitja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

availability; medicine expenditure; orphan medicines; patient access; rare disease

Indexed keywords

AMBRISENTAN; AZACITIDINE; BEVACIZUMAB; DASATINIB; DEFERASIROX; ELTROMBOPAG; ERLOTINIB; EVEROLIMUS; HUMAN GROWTH HORMONE; NILOTINIB; PAZOPANIB; SILDENAFIL; SUNITINIB; TOCILIZUMAB; TRABECTEDIN; DRUG;

ARTICLE; BULGARIA; CROATIA; EUROPEAN; FRANCE; GERMANY; GREECE; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; IRELAND; ITALY; MEDICINE; PRIORITY JOURNAL; RARE DISEASE; ROMANIA; SCANDINAVIA; UNITED KINGDOM; DRUG COST; DRUG MANUFACTURE; ECONOMICS; EUROPE; HEALTH CARE DELIVERY; STANDARDS; SUPPLY AND DISTRIBUTION;

DRUG COSTS; EUROPE; HEALTH SERVICES ACCESSIBILITY; HUMANS; ORPHAN DRUG PRODUCTION; PHARMACEUTICAL PREPARATIONS; RARE DISEASES;

EID: 85043778481     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2018.01.007     Document Type: Article

References (43)

1. European Medicines Agency. Orphan designation. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp&mid=WC0b01ac0580b18a41. Accessed November 5, 2016.
2. Orphanet. Rare disease registries in Europe. Available from: http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf. Accessed March 2, 2016.
3. Richter, T., Nestler-Parr, S., Babela, R., et al. Rare disease terminology and definitions—a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Heal 18 (2015), 906–914.
4. European Organisation for Rare Diseases (EURORDIS). About rare diseases. Available from: http://www.eurordis.org/about-rare-diseases. Accessed June 14, 2016.
5. Orphanet. The portal for rare diseases and orphan drugs. Available from: http://www.orpha.net/consor/cgi-bin/Education_AboutOrphanet.php?lng=EN. Accessed March 2, 2016.
6. European Commission. Regulation (EC) No 141/2000 of the European Parliament and of the Council. Available from: http://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf. Accessed August 23, 2016.
7. Innovative Medicines Initiative. Europe's partnership for health. Available from: https://www.imi.europa.eu/content/home. Accessed August 23, 2016.
8. Hughes-Wilson, W., Palma, A., Schuurman, A., et al. Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?. Orphanet J Rare Dis, 7, 2012, 74.
9. Orphanet. List of medicinal products for rare diseases in Europe. Available from: http://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf. Accessed March 2, 2016.
10. Côté A., Keating, B., What is wrong with orphan drug policies?. Value Heal 15 (2012), 1185–1191.
11. European Public Health Alliance. EPHA Briefing Document on Access to Medicines in times of Austerity. Available from: http://v2.epha.org/IMG/pdf/FINAL_EPHA_Briefing_on_Access_to_Medicines.pdf. Accessed June 26, 2016.
12. Wilson, A., Cohen, J., Patient access to new cancer drugs in the United States and Australia. Value Heal 14 (2011), 944–952.
13. Cohen, J., Faden, L., Predaris, S., et al. Patient access to pharmaceuticals: an international comparison. Eur J Heal Econ 8 (2007), 253–266.
14. Blankart, C.R., Stargardt, T., Schreyögg, J., Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia. Pharmacoeconomics 29 (2011), 63–82.
15. Gammie, T., Lu, C.Y., Babar, Z.U.-D., Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PloS One, 10, 2015, e0140002.
16. Kanavos, P., Nicod, E., What is wrong with orphan drug policies? Suggestions for ways forward. Value Heal 15 (2012), 1182–1184.
17. Drummond, M.F., Wilson, D.A., Kanavos, P., et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 23 (2007), 36–42.
18. Gericke, C.A., Riesberg, A., Busse, R., Ethical issues in funding orphan drug research and development. J Med Ethics 31 (2005), 164–168.
19. European Parliament, Directorat-general for internal policies. Differences in costs of and access to pharmaceutical products in the EU 2011. Executive summary. Available from: http://www.europarl.europa.eu/RegData/etudes/etudes/join/2011/451481/IPOL-ENVI_ET(2011)451481_EN.pdf. Accessed June 12, 2016.
20. Simoens, S., Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis, 6, 2011, 42.
21. Denis, A., Mergaert, L., Fostier, C., et al. A comparative study of European rare disease and orphan drug markets. Health Policy 97 (2010), 173–179.
22. Schey, C., Milanova, T., Hutchings, A., Estimating the budget impact of orphan medicines in Europe: 2010 - 2020. Orphanet J Rare Dis, 6, 2011, 62.
23. Orofino, J., Soto, J., Casado, M.A., et al. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy 8 (2010), 301–315.
24. Kanters, T.A., Steenhoek, A., Hakkaart, L., Orphan drugs expenditure in the Netherlands in the period 2006-2012. Orphanet J Rare Dis, 9, 2014, 154.
25. Logviss, K., Krievins, D., Purvina, S., Impact of orphan drugs on Latvian budget. Orphanet J Rare Dis, 11, 2016, 59.
26. World Health Organization. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research 2015. Available from: http://apps.who.int/medicinedocs/documents/s21793en/s21793en.pdf. Accessed July 26, 2017.
27. IMS PADDS Database viewer. IMS MIDAS Quarterly Sales Data, January 2005 – December 2014. Danbury, CT: IQVIA.
28. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2016. Available from: http://www.whocc.no/atc_ddd_index/. Accessed March 7, 2016.
29. World Health Organization. Global health expenditure database: indicators and data. Available from: http://apps.who.int/nha/database/Select/Indicators/en. Accessed June 18, 2016.
30. Organisation for Economic Co-operation and Development. OECD.Stat database. Pharmaceutical sales indicator. Available from: https://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_PHMC. Accessed June 20, 2016.
31. Trama, A., Pierannunzio, D., Loizzo, A., et al. Availability of medicines for rare diseases in EU Countries. Pharm Policy Law 11 (2009), 101–109.
32. Bignami, F., EURORDIS survey on orphan drugs availability in Europe, 2007 Available from: http://www.eurordis.org/IMG/pdf/2007ODsurvey-eurordis.pdf. Accessed September 3, 2016.
33. Le Cam, Y., Inventory of access and prices of orphan drugs across Europe: a Collaborative work between National Alliances on Rare Diseases & EURORDIS, 2010 Available from: http://img.eurordis.org/newsletter/pdf/mar-2011/ERTC_13122010_YLeCam_Final.pdf. Accessed August 23, 2016.
34. Richter, A., Assessing the impact of global price interdependencies. Pharmacoeconomics 26 (2008), 649–659.
35. Picavet, E., Dooms, M., Cassiman, D., et al. Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy 9 (2011), 275–279.
36. International Society for Pharmacoeconomics and Outcomes Research. Global healthcare systems roadmap. Available from: http://www.ispor.org/htaroadmaps/. Accessed September 15, 2016.
37. Young, K.E., Soussi, I., Hemels, M., et al. A comparative study of orphan drug prices in Europe. J Mark Access Heal Policy, 5, 2017, 1297886.
38. 2012 Report on the state of the art of rare disease activities in Europe of the European Union Committee of Experts on Rare Diseases 2012 – state of the art of rare disease activities in Slovenia. Available from: http://www.eucerd.eu/?post_type=document&p=1529. Accessed July 26, 2017.
39. Kamusheva, M., Stoimenova, A., Doneva, M., et al. A cross-country comparison of reimbursed orphan medicines in Bulgaria, Greece and Romania. Biotechnol Biotechnol Equip 27 (2013), 4186–4192.
40. Ades, F., Zardavas, D., Senterre, C., et al. Hurdles and delays in access to anti-cancer drugs in Europe. Ecancermedicalscience, 8, 2014, 482.
41. Report on the state of the art of rare disease activities in Europe of the European Union Committee of experts on rare diseases 2012 - state of the art of rare disease activities in Norway. Available from: http://www.eucerd.eu/?post_type=document&p=1510. Accessed July 26, 2017.
42. Orphanet. Prevalence and incidence of rare diseases: bibliographic data. Diseases listed by decreasing prevalence, incidence or number of published cases, 2016 Available from: http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf. Accessed October 15, 2016.
43. De Varax, A., Letellier, M., Börtlein, G., et al. Study on orphan drugs: overview of the conditions for marketing orphan drugs in Europe, 2006 Available from: http://ec.europa.eu/health//sites/health/files/files/orphanmp/doc/pricestudy/final_final_report_part_1_web_en.pdf. Accessed September 30, 2016.